ANN ARBOR, Mich., Aug. 8, 2008 (PRIME NEWSWIRE) -- MIR Preclinical Services (MIR) will be exhibiting at 5 major research conferences this fall. These conferences are described below:

1. World Molecular Imaging Congress, September 10th-13th, Nice, France: MIR will be showcasing the preclinical GMI PET/CT, Siemens R4 PET, Varian 7T MRI, GE RS150 CT and Xenogen IVIS bioluminescence and fluorescence systems it uses to perform client services. As the in vivo imaging leader in the contract research industry, MIR continues to develop innovations to increase the efficiency of preclinical drug development. Dr. Patrick McConville, Director of Imaging at MIR will be presenting a poster at the conference: ``Fluorine-19 nanoemulsion for MRI of an inflammatory response'' (Poster# 0616; Friday, September 12, 4-5PM).

2. International IRA Conference, September 21st-24th Chantilly, Virginia: MIR will be featuring its services such as Collagen Induced Arthritis (CIA), Collagen Antibody Induced Arthritis (CAIA), Adjuvant Induced Arthritis (AIA), LPS Induced Cytokine Release, Delayed Type Hypersensitivity (DTH), Carrageenan Induced Footpad Edema (CFE), Air Pouch Granuloma and custom models for the evaluation of novel anti-inflammatory agents. The use of preclinical imaging technologies in these models to measure response to therapy at anatomical, functional, and molecular levels will also be highlighted. Dr. Joe Cornicelli, Director of Inflammation Services at MIR will be presenting a seminar entitled ``Imaging an inflammatory response using 19F MRI'' (session#; time etc.).

3. EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Conference, October 21st-24th Geneva, Switzerland: MIR will be highlighting its services for the evaluation of novel anti-cancer agents using preclinical xenograft, syngeneic and orthotopic cancer models, as well as models of angiogenesis. The use of an array of preclinical in vivo imaging technologies in these models to measure response to therapy at anatomical, functional, and molecular levels will also be featured.

4. American College of Rheumatology Conference, October 26th-29th San Francisco, California: MIR will be emphasizing its services such as Collagen Induced Arthritis (CIA), Collagen Antibody Induced Arthritis (CAIA), Adjuvant Induced Arthritis (AIA), LPS Induced Cytokine Release, Delayed Type Hypersensitivity (DTH), Carrageenan Induced Footpad Edema (CFE), Air Pouch Granuloma and custom models for the evaluation of novel anti-inflammatory agents. MIR's preclinical in vivo imaging technologies in these models will also be showcased..

5. American Association of Pharmaceutical Scientists (AAPS) Conference, November 17th-19th Atlanta, Georgia: MIR will be highlighting all of its services for the evaluation of novel anti-cancer and anti-inflammatory agents. The company will also be focusing on the use of its in-house in vivo imaging technologies in these models to measure response to therapy at anatomical, functional, and molecular levels.

          MIR Preclinical Services
          Frank Urban, Sr. Manager, Business Development
          734-821-1063
          info@molecularimaging.com
          www.molecularimaging.com
          800 Technology Drive
          Ann Arbor, MI 48108